Jack Kaye Sells 2,645 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 2,645 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $30.01, for a total transaction of $79,376.45. Following the completion of the sale, the director owned 20,439 shares of the company’s stock, valued at approximately $613,374.39. This represents a 11.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

Shares of QURE stock opened at $26.45 on Friday. The firm has a 50-day moving average of $21.39 and a 200-day moving average of $21.86. The company has a market cap of $1.67 billion, a P/E ratio of -7.60 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Equities research analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Analyst Ratings Changes

QURE has been the subject of a number of research analyst reports. Barclays decreased their price objective on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday, March 23rd. Cantor Fitzgerald restated a “neutral” rating and set a $9.00 price objective (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. The Goldman Sachs Group raised their price objective on shares of uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. Finally, Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, uniQure has an average rating of “Moderate Buy” and a consensus price target of $42.83.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in uniQure by 15.7% during the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after purchasing an additional 152,417 shares during the period. Aberdeen Group plc boosted its position in uniQure by 6.9% during the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares during the period. Quinn Opportunity Partners LLC bought a new position in uniQure during the third quarter worth about $6,281,000. Farallon Capital Management LLC boosted its position in uniQure by 3,935.7% during the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after purchasing an additional 551,000 shares during the period. Finally, Boone Capital Management LLC bought a new position in uniQure during the third quarter worth about $8,599,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.